Current Abbvie Foundation Professor in Cancer Immunotherapy, Leader of the Immunology and Cancer program, Director of Melanoma Oncology, University of Chicago
Formerly President of the Society for Immunotherapy of Cancer
Published more than 200 papers in T cell biology, anti-tumor immunity, and melanoma therapy, including discovery of a role for the STING pathway, immune-evasive oncogenic events, and the microbiome
Editor for Journal of Experimental Medicine and Journal for Immunotherapy of Cancer
Recipient of numerous awards including the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research, the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy, and the Coley Award.
B.A., Ph.D., M.D., University of Chicago; Postdoctoral Fellow at Ludwig Institute for Cancer Research in Belgium and University of Chicago
Dr. Scott A. Biller
Over 35 years of experience in biopharma discovery and development.
Retired as CSO of Agios Pharmaceuticals at the end of 2019, a position he held for over 9 years. At Agios, Dr. Biller led efforts to discover two approved medicines, TIBSOVO® and IDHIFA® for AML harboring IDH1 and IDH2 mutations, respectively, a third, mitapivat (for pyruvate kinase deficiency) that recently completed two positive Phase 3 trials and a fourth, vorasidenib (for IDH-mutated low-fgrade glioma) which is currently in Phase 3.
Prior to Agios, Dr. Biller held senior R&D leadership roles at Novartis and BMS.
B.S. in chemistry from MIT, Ph.D. in organic chemistry from Caltech, NIH Postdoctoral Fellowship at Columbia University.
Dr. Dayao Zhao
CEO of AffaMed Therapeutics
Former General Manager of Pfizer China R&D Center and the head of Development China organization which is fully responsible for all clinical development in China for the global markets.
Former Head of China R&D of Johnson and Johnson’s pharmaceutical division and led JNJ China R&D to conduct numerous clinical trials and register many new products in China and around the world.
Former VP at Genzyme and headed up Genzyme’s Japan-Asia Pacific R&D where he had overall responsibilities for Clinical Development, Pharmacovigilance, Medical Affairs and Regulatory Affairs.
More than 12 years in both discovery and clinical development at Pfizer Central Research, and led the CNS clinical development team in North America at Novartis.
M.D.,Peiking University; PH.D., Harvard Medical School